On June 30, 2023, 111 ($NASDAQ:YI) reported its earnings results for the second quarter of fiscal year 2023 – achieving a total revenue of CNY 3477.5 million, which represented a 14.5% increase from the same quarter in the previous year. Additionally, the company recorded a net income of CNY -57.2 million, which was an improvement from -95.3 million in the second quarter of the prior year.
On Thursday, June 30th 2023, 111 reported their Q2 FY2023 earnings results. When the market opened, 111 stock opened at $3.0, but closed at $2.8, a decrease of 5.3% from the previous closing price of $2.9. This decrease in stock price demonstrates the uncertainty of the market in regards to the current fiscal quarter’s earnings for 111. The company also released their quarterly financial statements to provide insights on their current financial conditions.
However, their net income dropped by 5%, indicating that investments and other expenses may have impacted the company’s bottom line. Despite the dip in net income, 111 stockholders remain optimistic that the company will continue to improve their performance in the subsequent quarters. Overall, this news shows that investors and stockholders remain divided on the future performance of 111. Investors will need to analyze the company’s quarterly financials further to get a better understanding of the company’s prospects. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for 111. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 111. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 111. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for 111 are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – 111 Stock Fair Value
At GoodWhale, we have conducted an analysis of the fundamentals of 111. Our proprietary Valuation Line has calculated the intrinsic value of 111 to be around $5.8, while the current stock price is $2.8. This shows that the stock is currently undervalued by 52%. We believe this presents an interesting buying opportunity for investors who are looking to take advantage of the current market conditions. More…
Risk Rating Analysis
Star Chart Analysis
The company has a strong presence in the Chinese healthcare market and competes with other leading players such as China Jo-Jo Drugstores Inc, Health Advance Inc and Zur Rose Group AG. These companies are all well established providers of healthcare services, offering their respective customers a variety of products and services to choose from.
– China Jo-Jo Drugstores Inc ($NASDAQ:CJJD)
China Jo-Jo Drugstores Inc is a leading Chinese national retail drugstore chain that was founded in 2002. It is one of the largest retail drugstore chains in China, with more than 2,000 stores and sales outlets in over 200 cities across the country. As of 2022, the company has a market capitalization of 33.72M. Its Return on Equity (ROE) stands at -4.61%, indicating that the company is not generating a positive return on its shareholders’ investments. Despite this, China Jo-Jo Drugstores Inc’s strong presence in the Chinese market and its aggressive expansion plans make it an attractive investment option.
– Health Advance Inc ($OTCPK:HADV)
Health Advance Inc is a healthcare provider specializing in providing comprehensive and quality care to its patients. The company’s market capitalization stands at 984.94k as of 2022, which reflects its growth and stability in the industry. Its Return on Equity (ROE) of 57.91% is indicative of the company’s efficient use of its assets and capital to generate profits. Health Advance Inc’s impressive market cap and ROE are a testament to its continued success in providing quality care to its patients.
– Zur Rose Group AG ($LTS:0RRB)
Zur Rose Group AG is a Swiss e-commerce and mail-order pharmacy, providing customers with prescription and non-prescription medications, health and beauty products, and medical products. As of 2022, the company has a market capitalization of 357.78 million Swiss francs, indicating its value on the stock market. Furthermore, Zur Rose Group AG has a negative return on equity (ROE) of -29.55%, which is below average, indicating that the company’s management is not efficiently utilizing its shareholders’ equity to generate profits.
Investors were disappointed by 111‘s second quarter financial results for fiscal year 2023, as total revenue increased by only 14.5% compared to the same quarter in the previous year and net income declined from -95.3 million to -57.2 million. This caused the stock price to move down on June 30, 2023. Analysts suggest that 111 needs to focus on strengthening their financial performance in order to appease investors and restore confidence in their stock. In addition, they should look for strategic opportunities to unlock value and further increase their revenue growth.